All Eyes On Sun's Ophthalmology US NDA
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries' ophthalmology NDA BromSite (0.075% bromfenac), comes up for US regulatory approval next month, setting the stage for a potential push in a segment where the Indian firm has been prepping for a ramp up.